Blood Gas/Blood Gas Analyzers Market Seeing 4.6% CAGR to Reach $636 Million by 2021

The blood gas and blood gas analyzers market is expected to reach USD 636.0 million by 2021 from USD 506.9 million in 2016, at a CAGR of 4.6% dominated by North America driven by growing number of sepsis cases and high cost of treatment.

The global blood gas analyzers market is segmented based on players, major brands, and regions. GEM 3000 (Instrumentation Laboratory) is expected to account for the largest share of the global blood gas analyzers market in 2016, while ePOC (Alere) will be the fastest-growing product segment in the coming years.

Major factors driving the growth of blood gas and blood gas analyzers market include the rising geriatric population and the subsequent growth in prevalence of chronic diseases, and growing demand for point-of-care analyzers. Furthermore, the growth in demand for integrated combined systems and miniaturization of POC blood gas analyzers are expected to support market growth.

Complete report on Blood gas analyzer / blood gas and electrolyte analyzer market across 139 pages, profiling 9 companies and supported with 38 tables and 14 figures is now available at .

Geographically, the blood gas analyzers market is dominated by North America, followed by Europe, APAC, and the Rest of the World (RoW). Growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives are some of the key factors responsible for the large share of North America in the global market.

Asia-Pacific is estimated to be the fastest-growing regional segment during the forecast period. Japan, China, and India are the major contributors to the Asia-Pacific blood gas analyzers market. Factors such as growing initiatives by market players, increasing patient population base, and rising number of partnerships and joint ventures are driving the Asia-Pacific market.

The blood gas analyzer market is segmented on the basis of major product brands (i-STAT, epoc, GEM 3000, GEM 3500, GEM 4000, ABL800, ABL80, ABL90, cobas b 221, cobas b 121, cobas b 123, RAPID Series) in four major regional segments, namely, North America, Europe, APAC, and Rest of the World. This report analyzes the market from both value and volume perspectives. GEM 3000 is expected to account for the largest share of the global blood gas analyzers market in 2016. This is mainly because GEM 3000 delivers real-time system diagnostics, requires low labor-intensive system calibration, and eliminates lengthy equipment training and possible human errors. On the other hand, epoc (Alere) is expected to be the fastest-growing brand in the coming years.

This report provides market sizing of companies and their brands in terms of value and volume (per-year sales). In addition to market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. Also, company profiles comprise the product portfolios, developments, and strategies adopted by market players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach and levels of output in order to remain successful in the market.

The major players in the global blood gas analyzers market are Abbott Laboratories (U.S.), Alere, Inc. (U.S.), Instrumentation Laboratory (U.S.), Radiometer (Denmark), Roche Diagnostics (Switzerland), and Siemens Healthcare (Germany).

Get a discount on this report at .

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned strategies (New product launches, M&As, agreements and collaborations, others (webinars, website launch, company rebranding and investment)) for strengthening their market shares.

On a related note, another research on Blood Culture Tests Market Global Forecast to 2021 says, the global blood culture tests market is projected to reach USD 4,768.9 million by 2021 from USD 3,252.6 million in 2016, at a CAGR of 8.0%. North America commanded the largest share of the global blood culture tests market in 2015. Factors such as high cost of automated instruments and lack of technically skilled professionals are restraining the growth of this market. Companies like Becton, Dickinson and Company, Biomérieux SA, Thermo Fisher Scientific, Inc., Cepheid, Nanosphere, Inc., Bruker Corporation, Beckman Coulter (Wholly Owned Subsidiary of Danaher Corporation), Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd.), Iridica (A Subsidiary of Abbott Laboratories) and T2 Biosystems have been profiled in this 249 pages research report available at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets.

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: RNR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar
Phone: +1-888-391-5441

Release ID: 123534